GET DAILY SIGNALSPulmonx (LUNG) Delivers +6% Revenue Growth and Narrows Losses in Q3 2026
Key Takeaways
- Pulmonx reported third quarter 2026 revenue of $22.8 million, up 6% year over year and above the consensus estimate of $21.93 million.
- Net loss narrowed 40% to $8.4 million, or $0.19 per share, beating the consensus expectation of a $0.26 per-share loss.
- Gross margin improved to 76%, and management raised its full-year 2026 gross margin outlook to approximately 77%.
- Operating expenses fell 18% to $24.9 million, underscoring the company's cost-reduction efforts.
- Management reiterated full-year 2026 revenue guidance of $90 million to $92 million.
- Adjusted EBITDA loss narrowed nearly 60% to $3.5 million.
Earnings Context and Why It Matters
Pulmonx Corporation (LUNG) is a medical technology company focused on minimally invasive treatments for chronic obstructive pulmonary disease (COPD), a progressive lung condition. Its flagship Zephyr Endobronchial Valve treats patients with severe emphysema. The third quarter of 2026 marked a pivotal moment: the company returned to year-over-year revenue growth in both its U.S. and international businesses for the first time since its current leadership team rejoined the company. Coming after a period of commercial reset, this report offers investors a key signal on whether Pulmonx's rebuilt sales organization and cost discipline can translate into sustained top-line expansion and a clearer path toward profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Pulmonx reported total worldwide revenue of $22.8 million for the third quarter ended September 30, 2026, a 6% increase from $21.5 million in the prior-year period and above the $21.93 million consensus estimate. U.S. revenue rose 7% to $14.9 million, while international revenue increased 5% to $7.9 million. Excluding China, international markets grew approximately 9% year over year.
GAAP net loss narrowed to $8.4 million, or $0.19 per share, compared with a net loss of $14.0 million, or $0.34 per share, in the same quarter last year. The result beat the consensus EPS estimate of a $0.26 loss.
Gross margin was 76%, up from 75% a year earlier, while total operating expenses declined 18% to $24.9 million. Adjusted EBITDA loss narrowed to $3.5 million from $8.2 million, reflecting meaningful operating leverage. The company ended the quarter with $52.7 million in cash and cash equivalents.
Pulmonx also updated its outlook, reiterating full-year 2026 revenue guidance of $90 million to $92 million and raising its gross margin expectation to approximately 77%. Full-year operating expenses are now expected to land between $108 million and $109 million.
Market Reaction and Investor Sentiment
The market responded favorably to Pulmonx's third-quarter results. According to Investing.com, shares jumped roughly 13% after the report as investors rewarded the company's return to revenue growth, the EPS beat, and the narrowed losses. Sentiment has been supported by Pulmonx's consistent record of exceeding consensus EPS estimates and by management's confirmation of full-year guidance. The addition of eight new U.S. treating centers during the quarter and the renewed China registration certificate also reinforced confidence that commercial momentum is rebuilding. Investors appeared to interpret the results as evidence that the company's restructuring and cost-reduction strategy is gaining traction. From what I see, this kind of reaction often signals building conviction when fundamentals align with guidance.
Forward Outlook and Key Factors to Monitor
Looking ahead, several factors will shape Pulmonx's trajectory through the remainder of 2026 and into 2027. First, investors should monitor the productivity ramp of the rebuilt U.S. sales force. Management indicated that substantially all open U.S. sales positions have been filled, but average sales representative tenure remains relatively short, meaning continued execution will be central to sustaining growth.
Second, the China business represents a potential near-term catalyst. With the registration certificate renewed, Pulmonx expects to resume shipments to its distributor by early next year, which could add incremental revenue as the region comes back online.
Third, watch progress on the AeriSeal platform. Enrollment in the CONVERT2 pivotal trial continues, and management views AeriSeal as a market-expansion opportunity that could broaden the company's addressable market by roughly 20%.
Finally, keep an eye on margins and cash usage. Pulmonx now expects roughly $22 million of cash burn for full-year 2026, a 30% reduction from 2025, and raised its gross margin outlook to about 77%. Sustained operating leverage combined with renewed revenue growth will be the key test of whether the company can continue narrowing losses toward its long-term profitability goals. I’m watching this closely as execution here could define the stock’s next leg higher.
Using Tickeron’s AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Screener can help investors quickly compare LUNG against peers on metrics such as revenue trends, margin expansion, and technical signals. I often run similar screens when evaluating medtech names to spot patterns that might not stand out in standard reports. This approach has added useful context to my review of the quarter without replacing the core fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LUNG's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for LUNG turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on LUNG as a result. In 68 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +3.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
LUNG moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LUNG crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.137) is normal, around the industry mean (3.847). P/E Ratio (-1.696) is within average values for comparable stocks, (1.909). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement